Cryolife Gross Profit

The latest gross profit for CRY is $300M as of March 2026. That compares with $250M in the prior-year period — up 20.6% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside Cryolife's historical trend and sector peers before judging valuation or financial health.

Over the past year, CRY's gross profit moved from $250M to $300M — a 20.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cryolife's operating scale or balance-sheet position.

Against Healthcare companies, CRY currently prints $300M for gross profit, while the sector average sits near $67B. That is roughly 99.6% below the sector mean. Large gaps often invite a closer look at Cryolife's growth, margins, and balance sheet.

A gross profit figure of $300M for CRY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting CRY's gross profit ($300M), review year-over-year change from $250M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.